Regenxbio Inc to Host Virtual Investor Day Transcript
Welcome to our REGENXBIO Virtual Investor Day event. I am Ken Mills, CEO of REGENXBIO. I'm pleased to introduce our agenda and make some opening remarks. For this event, we have a program to provide an update on the company's pipeline with a focus on programs with expected interim clinical trial data to present in the second half of 2023.
Among other things today, we'll introduce some new interim safety data from our AAVIATE and ALTITUDE clinical trials, a new pipeline program for the treatment of Duchenne and some specific guidance about additional interim trial updates later this year. We're also pleased to be introduced by 3 external experts who are leaders in the fields of Duchenne research and retinal disease. Professor Dickson and Dr. Kaiser and Sheth will enjoy, engage with management in a discussion, each program review and participate in our live Q&A session at the end of the program. I'm grateful for George, Peter and Veeral to join us today.
(Operator Instructions) Today's event will include forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
